DPP-4 inhibitor dose selection according to manufacturer specifications: A Contemporary Experience From UK General Practice

Dionysis Spanopoulos, Michael Busse, Joanne Webb, Abigail Tebboth, Nicholas D. Gollop, Michael W. Marcus

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
3 Downloads (Pure)

Abstract

Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.

Original languageEnglish
Pages (from-to)1622-1630
Number of pages9
JournalClinical Therapeutics
Volume41
Issue number8
Early online date1 Jun 2019
DOIs
Publication statusPublished - Aug 2019
Externally publishedYes

Keywords

  • dose selection
  • DPP-4 inhibitors
  • summary of product characteristics
  • renal impairment
  • Type 2 diabetes mellitus
  • UK general practice
  • TYPE-2 DIABETES-MELLITUS
  • PEPTIDASE 4 INHIBITORS

Cite this